CRIS

Stock Update (NASDAQ:CRIS): Curis, Inc. Announces Publication of CUDC-907 Phase 1 Clinical Trial Data in Lancet Oncology

Curis, Inc. (NASDAQ:CRIS), a biotechnology company focused on the development and commercialization of innovative and effective drug candidates for the treatment of human cancers, …

Corey Williams — April 4, 2016, 7:31 AM EDT

Company Update (NASDAQ:CRIS): Curis, Inc. Reports Fourth Quarter and Year-End 2015 Financial Results

Curis, Inc. (NASDAQ:CRIS), a biotechnology company focused on the development and commercialization of innovative drug candidates for the treatment of human cancers, today reported …

Corey Williams — February 29, 2016, 9:17 AM EDT

Stock Update (NASDAQ:CRIS): Curis, Inc. Expands Cancer Drug Pipeline With Small Molecule PD-L1/ VISTA Immune Checkpoint Antagonist and IRAK4 Kinase Inhibitors

Curis, Inc. (NASDAQ:CRIS), a biotechnology company focused on the development and commercialization of innovative drug candidates for the treatment of human cancers, today announced …

Corey Williams — October 19, 2015, 7:19 AM EDT

Curis, Inc. (CRIS) Reports Second Quarter 2015 Financial Results

Curis, Inc. (NASDAQ:CRIS), a biotechnology company focused on the development and commercialization of innovative drug candidates for the treatment of human cancers, today reported …

Corey Williams — August 6, 2015, 7:18 AM EDT

Biotech Jumps and Slumps: ISIS Pharmaceuticals, Inc., Nektar Therapeutics, Curis, Inc.

Isis Pharmaceuticals It can be very difficult to find companies that are both flying under the radar, and still might have potential for …

Zacks Equity Research Zacks Equity Research — June 29, 2015, 10:38 AM EDT

Company Update (NASDAQ:CRIS): Curis, Inc. Reports CUDC-907 Data From the Ongoing Phase 1 Trial at the 2015 ASCO Annual Meeting

Curis, Inc. (NASDAQ:CRIS), a biotechnology company focused on the development and commercialization of innovative drug candidates for the treatment of human cancers, announced …

Corey Williams — June 1, 2015, 10:31 AM EDT

Company Update (NASDAQ:CRIS): Curis, Inc. Reports First Quarter 2015 Financial Results

Curis, Inc. (NASDAQ:CRIS), a biotechnology company focused on the development and commercialization of innovative drug candidates for the treatment of human cancers, today …

Corey Williams — May 7, 2015, 7:20 AM EDT

Stock Update (NASDAQ:CRIS): Curis, Inc. Presents Preclinical Data on CUDC-427 at AACR Annual Meeting

Curis, Inc. (NASDAQ:CRIS), a biotechnology company focused on the development and commercialization of innovative drug candidates for the treatment of human cancers, announced …

Corey Williams — April 22, 2015, 8:15 AM EDT

Stock Update (NASDAQ:CRIS): Curis, Inc. Announces Presentation of Data from CUDC-427 and IRAK-4 Programs at AACR Annual Meeting

Curis, Inc. (Nasdaq:CRIS), a biotechnology company focused on the development and commercialization of innovative drug candidates for the treatment of human cancers, today announced …

Corey Williams — April 16, 2015, 4:19 PM EDT

Company Update (NASDAQ:CRIS): Curis, Inc. Announces Orphan Drug Designation for CUDC-907 in Diffuse Large B-Cell Lymphoma

Curis, Inc. (NASDAQ:CRIS), a biotechnology company focused on the development and commercialization of innovative drug candidates for the treatment of human cancers, announced …

Corey Williams — April 6, 2015, 7:08 AM EDT

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts